These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 1895414)

  • 21. The change of penile blood thromboxane B2 and prostacyclin after intracavernous injection of vasoactive drugs for the treatment of arteriogenic impotence.
    Lin JS; Chang WC; Lui SM
    Proc Natl Sci Counc Repub China B; 1994 Jan; 18(1):12-6. PubMed ID: 8029369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction.
    Bechara A; Casabé A; Chéliz G; Romano S; Rey H; Fredotovich N
    J Urol; 1997 Jun; 157(6):2132-4. PubMed ID: 9146599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of re-dosing of vasodilators on the intracavernosal pressure and on the penile rigidity.
    de Meyer JM; Thibo P
    Eur Urol; 1998; 33(3):293-6; discussion 296-7. PubMed ID: 9555555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [3 years' experience with intracavernous auto-injection therapy].
    Weiske WH
    Urologe A; 1989 Sep; 28(5):253-6. PubMed ID: 2815435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Alprostadil (Caverject) and a combination of vasoactive drugs as local injections for the treatment of erectile dysfunction.
    Abdallah HM
    Int Urol Nephrol; 1998; 30(5):617-20. PubMed ID: 9934808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1.
    Seyam R; Mohamed K; Akhras AA; Rashwan H
    Int J Impot Res; 2005; 17(4):346-53. PubMed ID: 15772683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prostaglandin E1 dose-response study in man.
    von Heyden B; Donatucci CF; Marshall GA; Brock GB; Lue TF
    J Urol; 1993 Dec; 150(6):1825-8. PubMed ID: 8230515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of effects following the intracorporeal injection of papaverine and prostaglandin E1.
    Chen JK; Hwang TI; Yang CR
    Br J Urol; 1992 Apr; 69(4):404-7. PubMed ID: 1581812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological erection program using prostaglandin E1.
    Gerber GS; Levine LA
    J Urol; 1991 Sep; 146(3):786-9. PubMed ID: 1875494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Papaverine and prostaglandin E1 gel applications for impotence.
    Chiang HS; Kao YH; Sheu MT
    Ann Acad Med Singap; 1995 Sep; 24(5):767-9. PubMed ID: 8579329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The lowest effective dose of prostaglandin E1 as treatment for erectile dysfunction.
    Chen J; Godschalk M; Katz PG; Mulligan T
    J Urol; 1995 Jan; 153(1):80-1. PubMed ID: 7966797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Experience with triple-drug therapy in a pharmacological erection program.
    Govier FE; McClure RD; Weissman RM; Gibbons RP; Pritchett TR; Kramer-Levien D
    J Urol; 1993 Dec; 150(6):1822-4. PubMed ID: 8230514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents.
    Kiely EA; Bloom SR; Williams G
    Br J Urol; 1989 Aug; 64(2):191-4. PubMed ID: 2765789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of multidose intracorporeal injection and audiovisual sexual stimulation in vasculogenic impotence.
    Katlowitz N; Albano GJ; Patsias G; Golimbu M; Morales P
    Urology; 1993 Dec; 42(6):695-7. PubMed ID: 8256402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical evaluation of intracavernous self-injection of vasoactive drugs for impotence: a long-term follow-up observation].
    Hayashi S; Iwai Y; Yasumoto R; Matsuda J; Kawano M; Omachi T; Kono T; Yamamoto S; Sakakura T; Minami H
    Hinyokika Kiyo; 1994 Jan; 40(1):37-41. PubMed ID: 7509119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence.
    Ishii N; Watanabe H; Irisawa C; Kikuchi Y; Kubota Y; Kawamura S; Suzuki K; Chiba R; Tokiwa M; Shirai M
    J Urol; 1989 Feb; 141(2):323-5. PubMed ID: 2913354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Evaluation of clinical usefulness of direct drug injections for increasing local circulation, into cavernous bodies of the penis for treatment of erection impotence in patients with diabetes mellitus].
    Dembe K; Jasik M; Piechna K
    Pol Tyg Lek; 1994 Jan 3-17; 49(1-3):19-20. PubMed ID: 8008670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prostaglandin E1 injection in erectile dysfunction. Current diagnostic and therapeutic possibilities].
    Schrey A
    Fortschr Med; 1990 Oct; 108(30):577-80. PubMed ID: 2245960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
    Vardi Y; Lidgi S; Moskovitz B; Levin RD
    Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective double-blind trial of intracorporeal papaverine versus prostaglandin E1 in the treatment of impotence.
    Sarosdy MF; Hudnall CH; Erickson DR; Hardin TC; Novicki DE
    J Urol; 1989 Mar; 141(3):551-3. PubMed ID: 2645420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.